A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients
Status:
Completed
Trial end date:
2019-06-19
Target enrollment:
Participant gender:
Summary
This is a phase I, open-label study to assess the safety, tolerability, pharmacokinetics and
preliminary anti-tumor activity of MEDI9447 in Japanese patients with advanced solid
malignancies.This study consists of 2 cohorts. Cohort 1 (dose level 1) and Cohort 2 (dose
level 2). At least 3 or up to 6 evaluable Japanese patients with advanced solid malignancies
will be enrolled in each cohort.